- The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment.
- The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide.
- "Sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in COVID-19 cases caused by the Omicron BA.2 sub-variant," the FDA said in a statement.
- Related: FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant.
- In a filing with the Securities and Exchange Commission, Vir Biotechnology said the companies were preparing a package of data to support the use of a higher dose of sotrovimab for the Omicron BA.2 sub-variant.
- Vir and GSK still expect to commence two Phase 3 trials this quarter to assess the use of sotrovimab in uninfected immunocompromised patients to determine whether sotrovimab can prevent symptomatic Covid infection.
- Price Action: GSK shares are up 1.86% at $45.40, and VIR stock is down 2.83% at $21.79 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks